牛牛AI助理已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on February 20, 2024, the publication of new data in the International Journal of Molecular Sciences demonstrating that its investigational drug opaganib significantly improves long-term survival in a mouse model of lung damage following ionizing radiation exposure. The study indicates opaganib's potential as a medical countermeasure against radiation-induced lung inflammation and fibrosis. Opaganib, a selective sphingosine kinase-2 (SPHK2) inhibitor, is being developed for multiple indications, including Acute Radiation Syndrome (ARS), COVID-19, and oncology. The U.S. National Institutes of Health's Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for its Product Development Program. The drug, which is easy to administer and has a five-year shelf-life, could be stockpiled by governments for use in radiological or nuclear incidents, pending FDA approval. The publication also highlights opaganib's potential benefits in cancer radiotherapy and its host-directed mechanism, which may maintain efficacy against emerging viral variants.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on February 20, 2024, the publication of new data in the International Journal of Molecular Sciences demonstrating that its investigational drug opaganib significantly improves long-term survival in a mouse model of lung damage following ionizing radiation exposure. The study indicates opaganib's potential as a medical countermeasure against radiation-induced lung inflammation and fibrosis. Opaganib, a selective sphingosine kinase-2 (SPHK2) inhibitor, is being developed for multiple indications, including Acute Radiation Syndrome (ARS), COVID-19, and oncology. The U.S. National Institutes of Health's Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for its Product Development Program. The drug, which is easy to administer and has a five-year shelf-life, could be stockpiled by governments for use in radiological or nuclear incidents, pending FDA approval. The publication also highlights opaganib's potential benefits in cancer radiotherapy and its host-directed mechanism, which may maintain efficacy against emerging viral variants.
專業生物製藥公司RedHill Biopharma Ltd. 於2024年2月20日宣佈，在《國際分子科學雜誌》上發佈新數據，表明其研究藥物奧帕加尼布顯著改善了電離輻射暴露後肺損傷小鼠模型的長期存活率。該研究表明，奧帕加尼布有可能作爲一種針對輻射引起的肺部炎症和纖維化的醫學對策。奧帕加尼布是一種選擇性鞘氨醇激酶-2（SPHK2）抑制劑，正在開發用於多種適應症，包括急性輻射綜合症（ARS）、COVID-19 和腫瘤學。美國國立衛生研究院的輻射與覈對策計劃（RNCP）已選擇奧帕加尼布作爲其產品開發計劃。這種藥物易於使用，保質期爲五年，在等待美國食品藥品管理局批准之前，政府可以儲存用於放射性或核事故。該出版物還重點介紹了奧帕加尼布在癌症放射治療中的潛在益處及其宿主導機制，該機制可能會保持對新出現的病毒變異的療效。
專業生物製藥公司RedHill Biopharma Ltd. 於2024年2月20日宣佈，在《國際分子科學雜誌》上發佈新數據，表明其研究藥物奧帕加尼布顯著改善了電離輻射暴露後肺損傷小鼠模型的長期存活率。該研究表明，奧帕加尼布有可能作爲一種針對輻射引起的肺部炎症和纖維化的醫學對策。奧帕加尼布是一種選擇性鞘氨醇激酶-2（SPHK2）抑制劑，正在開發用於多種適應症，包括急性輻射綜合症（ARS）、COVID-19 和腫瘤學。美國國立衛生研究院的輻射與覈對策計劃（RNCP）已選擇奧帕加尼布作爲其產品開發計劃。這種藥物易於使用，保質期爲五年，在等待美國食品藥品管理局批准之前，政府可以儲存用於放射性或核事故。該出版物還重點介紹了奧帕加尼布在癌症放射治療中的潛在益處及其宿主導機制，該機制可能會保持對新出現的病毒變異的療效。
有用
沒用